An Open-Label, Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Aged 18 to 65 years, inclusive, at the time of signing the ICF. * Body mass index between 18.0 and 30.5 kg/m2, inclusive. * No clinically significant findings on screening evaluations (clinical, laboratory, and ECG). * Ability to swallow and retain oral medication. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disea…